{"title":"CAR - T细胞治疗后CD19+淋巴瘤患者获益于huCAR19-IL18细胞","authors":"Diana Romero","doi":"10.1038/s41571-025-01036-8","DOIUrl":null,"url":null,"abstract":"<p>More than half of patients with relapsed and/or refractory B cell lymphomas who receive CD19-targeted chimeric antigen receptor (CAR) T cells do not have long-term remission. Furthermore, limited evidence is available on the effectiveness of subsequent treatment options for these patients, the majority of whom have CD19<sup>+</sup> disease at relapse. Now, data from a phase I trial demonstrate that the autologous IL-18-armoured CAR T cell product huCART19-IL18 is safe and efficacious in this setting.</p><p>The trial involved adult patients with CD19<sup>+</sup> B cell lymphomas (including diffuse large B cell lymphomas and follicular lymphomas in 38% and 29% of patients, respectively) who had previously received a median of seven previous lines of therapy including CD19-targeted CAR T cells. Of 28 patients enrolled, 21 received huCART19-IL18 cells. Of note, cell-product manufacturing failed for only one patient.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"18 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Benefit from huCAR19-IL18 cells in patients with CD19+ lymphomas after CAR T cells\",\"authors\":\"Diana Romero\",\"doi\":\"10.1038/s41571-025-01036-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>More than half of patients with relapsed and/or refractory B cell lymphomas who receive CD19-targeted chimeric antigen receptor (CAR) T cells do not have long-term remission. Furthermore, limited evidence is available on the effectiveness of subsequent treatment options for these patients, the majority of whom have CD19<sup>+</sup> disease at relapse. Now, data from a phase I trial demonstrate that the autologous IL-18-armoured CAR T cell product huCART19-IL18 is safe and efficacious in this setting.</p><p>The trial involved adult patients with CD19<sup>+</sup> B cell lymphomas (including diffuse large B cell lymphomas and follicular lymphomas in 38% and 29% of patients, respectively) who had previously received a median of seven previous lines of therapy including CD19-targeted CAR T cells. Of 28 patients enrolled, 21 received huCART19-IL18 cells. Of note, cell-product manufacturing failed for only one patient.</p>\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":\"18 1\",\"pages\":\"\"},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2025-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41571-025-01036-8\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-025-01036-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Benefit from huCAR19-IL18 cells in patients with CD19+ lymphomas after CAR T cells
More than half of patients with relapsed and/or refractory B cell lymphomas who receive CD19-targeted chimeric antigen receptor (CAR) T cells do not have long-term remission. Furthermore, limited evidence is available on the effectiveness of subsequent treatment options for these patients, the majority of whom have CD19+ disease at relapse. Now, data from a phase I trial demonstrate that the autologous IL-18-armoured CAR T cell product huCART19-IL18 is safe and efficacious in this setting.
The trial involved adult patients with CD19+ B cell lymphomas (including diffuse large B cell lymphomas and follicular lymphomas in 38% and 29% of patients, respectively) who had previously received a median of seven previous lines of therapy including CD19-targeted CAR T cells. Of 28 patients enrolled, 21 received huCART19-IL18 cells. Of note, cell-product manufacturing failed for only one patient.
期刊介绍：
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
